exposure. Adverse events were included based on one or more of the following factors: severity, frequency of reporting, or strength of evidence for a causal relationship to Fluzone. Thrombocytopenia, lymphadenopathy Blood and Lymphatic System Disorders: Anaphylaxis, other allergic/hypersensitivity reactions (including Immune System Disorders: urticaria, angioedema) Ocular hyperemia Eye disorders: syndrome (GBS), convulsions, febrile convulsions, Nervous System Disorders: myelitis (including encephalomyelitis and transverse myelitis), facial palsy (Bell’s palsy), optic neuritis/neuropathy, brachial neuritis, syncope (shortly after vaccination), dizziness, paresthesia Vasculitis, vasodilation/flushing Vascular Disorders: Dyspnea, pharyngitis, rhinitis, cough, Respiratory, Thoracic and Mediastinal Disorders: wheezing, throat tightness Stevens-Johnson syndrome Skin and Subcutaneous Tissue Disorders: Pruritus, asthenia/fatigue, pain in General Disorders and Administration Site Conditions: extremities, chest pain Vomiting Gastrointestinal Disorders: DOSAGE AND ADMINISTRATION FluQuadri/FluQuadri Junior should be given in accordance with the national recommendation as per the current Immunisation Handbook. Administration should be carried out by the intramuscular route. The dose and schedule are as follows: Children aged 6 months to 35 months: 0.25 mL dose Children and adults 3 years of age and older 0.5 mL dose For children who have not been adequately primed based on influenza vaccination history, a second dose should be administered approximately 4 weeks apart. Refer to the current Immunisation Handbook for the recommended doses of influenza vaccine for young children at different ages. Inspect FluQuadri/FluQuadri Junior visually for particulate matter and/or discolouration prior to administration. If any of these defects or conditions exist, the vaccine should not be administered. Before administering a dose of vaccine, shake the prefilled syringe. The syringe is for single use only and must not be reused.
exposure. Adverse events were included based on one or more of the following factors: severity, frequency of reporting, or strength of evidence for a causal relationship to Fluzone. Blood and Lymphatic System Disorders: Thrombocytopenia, lymphadenopathy Immune System Disorders: Anaphylaxis, other allergic/hypersensitivity reactions (including urticaria, angioedema) Eye disorders: Ocular hyperemia Nervous System Disorders: syndrome (GBS), convulsions, febrile convulsions, myelitis (including encephalomyelitis and transverse myelitis), facial palsy (Bell’s palsy), optic neuritis/neuropathy, brachial neuritis, syncope (shortly after vaccination), dizziness, paresthesia Vascular Disorders: Vasculitis, vasodilation/flushing Respiratory, Thoracic and Mediastinal Disorders: Dyspnea, pharyngitis, rhinitis, cough, wheezing, throat tightness Skin and Subcutaneous Tissue Disorders: Stevens-Johnson syndrome General Disorders and Administration Site Conditions: Pruritus, asthenia/fatigue, pain in extremities, chest pain Gastrointestinal Disorders: Vomiting DOSAGE AND ADMINISTRATION FluQuadri/FluQuadri Junior should be given in accordance with the national recommendation as per the current Immunisation Handbook. Administration should be carried out by the intramuscular route. The dose and schedule are as follows: Children aged 6 months to 35 months: 0.25 mL dose Children and adults 3 years of age and older 0.5 mL dose For children who have not been adequately primed based on influenza vaccination history, a second dose should be administered approximately 4 weeks apart. Refer to the current Immunisation Handbook for the recommended doses of influenza vaccine for young children at different ages. Inspect FluQuadri/FluQuadri Junior visually for particulate matter and/or discolouration prior to administration. If any of these defects or conditions exist, the vaccine should not be administered. Before administering a dose of vaccine, shake the prefilled syringe. The syringe is for single use only and must not be reused.
auspar-influenza-virus-haemagglutinin-150206-pi.docx